The Clinical Effects of Laser Acupuncture on Hospitalized Patients With Severe COVID-19: A Randomized Clinical Trial

被引:0
|
作者
Shojaeddin, Arista [1 ]
Fatemi, Alireza [2 ]
Razzaghi, Zahra [1 ]
Pishgahi, Mehdi [3 ]
Sherafat, Somayeh Jahani [1 ]
Razzaghi, Mohammadreza [1 ]
Shahrzad, Mohamad Karim [4 ]
Anaraki, Nafiseh [4 ]
Salehi, Chiman [4 ]
Amiri, Aslan [4 ]
机构
[1] Shahid Beheshti Univ Med Sci, Laser Applicat Med Sci Res Ctr, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Cardiol Dept, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Shohada Tajrish Hosp, Internal Med & Endocrinol Dept, Tehran, Iran
关键词
Laser acupuncture; Laser therapy; COVID-19; Severity; THERAPY LLLT; PAIN; IRRADIATION; IL-1-BETA; RELEVANCE; ASTHMA; BLIND; LUNG; ACTS;
D O I
10.34172/jlms.2023.14
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: The coronavirus disease (COVID-19) was extended to the entire population in China and around the world, and its mortality rate was about 3.4%. The impact of laser therapy on chronic respiratory diseases has been shown in previous studies. This study was aimed at examining the effects of laser acupuncture (LA) on patients with severe COVID-19. Methods: In the present study, 60 patients with a positive reverse transcription-polymerase chain reaction (RT-PCR) test were assigned to the intervention and control groups (30 patients in each group). The intervention group was treated with LA, that is, laser light with low energy on acupuncture points, once a day for five consecutive days. Results: The participants' mean age in the intervention and control groups was 48.96 +/- 12.65 and 53.16 +/- 12.28 respectively; 70% of the patients were male and 30% of them were female. IL6 had a significant reduction in the intervention group (P value = 0.038) in comparison with the control group (P value = 0.535). Furthermore, the mean admission time in the control group was significantly higher than that in the intervention group (P value = 0.047). However, the mortality rate in the intervention group was zero, but three patients in the control group died. Conclusion: Our study showed that LA can be used as supportive therapy for routine treatment in patients with severe COVID-19. Moreover, due to LA safety and it's low cost, it could be recommended as an adjuvant to conventional therapy in patients interested in treating their disease with such a method.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
    Darazam, Ilad Alavi
    Shokouhi, Shervin
    Mardani, Masoud
    Pourhoseingholi, Mohamad Amin
    Rabiei, Mohammad Mahdi
    Hatami, Firouze
    Shabani, Minoosh
    Moradi, Omid
    Gharehbagh, Farid Javandoust
    Irvani, Seyed Sina Naghibi
    Amirdosara, Mahdi
    Hajiesmaeili, Mohammadreza
    Rezaei, Omidvar
    Khoshkar, Ali
    Lotfollahi, Legha
    Gachkar, Latif
    Dehbsneh, Hadiseh Shabanpour
    Khalili, Negar
    Soleymaninia, Azam
    Kusha, Akram Hoseyni
    Shoushtari, Maryam Taleb
    Torabinavid, Parham
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99
  • [2] Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
    Ivan O. Rosas
    George Diaz
    Robert L. Gottlieb
    Suzana M. Lobo
    Philip Robinson
    Bradley D. Hunter
    Adilson W. Cavalcante
    J. Scott Overcash
    Nicola A. Hanania
    Alan Skarbnik
    Julia Garcia-Diaz
    Ivan Gordeev
    Jordi Carratalà
    Oliver Gordon
    Emily Graham
    Nicholas Lewin-Koh
    Larry Tsai
    Katie Tuckwell
    Huyen Cao
    Diana Brainard
    Julie K. Olsson
    Intensive Care Medicine, 2021, 47 : 1258 - 1270
  • [3] Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
    Rosas, Ivan O.
    Diaz, George
    Gottlieb, Robert L.
    Lobo, Suzana M.
    Robinson, Philip
    Hunter, Bradley D.
    Cavalcante, Adilson W.
    Overcash, J. Scott
    Hanania, Nicola A.
    Skarbnik, Alan
    Garcia-Diaz, Julia
    Gordeev, Ivan
    Carratala, Jordi
    Gordon, Oliver
    Graham, Emily
    Lewin-Koh, Nicholas
    Tsai, Larry
    Tuckwell, Katie
    Cao, Huyen
    Brainard, Diana
    Olsson, Julie K.
    INTENSIVE CARE MEDICINE, 2021, 47 (11) : 1258 - 1270
  • [4] The Adjunctive Effects of Acupuncture for Hospitalized COVID-19 Patients: a Single-Blinded Randomized Clinical Study
    Helianthi, Dwi Rachma
    Barasila, Atikah C.
    Harris, Salim
    Sinto, Robert
    Khaedir, Yordan
    Irman
    JOURNAL OF ACUPUNCTURE AND MERIDIAN STUDIES, 2022, 15 (04) : 247 - 254
  • [5] Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial
    Sarhan, Rania M.
    Altyar, Ahmed E.
    Warda, Ahmed Essam Abou
    Saied, Yasmine Mohamed
    Ibrahim, Haytham Soliman Ghareeb
    Schaalan, Mona F.
    Fathy, Shaimaa
    Sarhan, Neven
    Boshra, Marian S.
    PHARMACEUTICALS, 2023, 16 (04)
  • [6] Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial
    Matino, Erica
    Tavella, Elena
    Rizzi, Manuela
    Avanzi, Gian Carlo
    Azzolina, Danila
    Battaglia, Antonio
    Becco, Paolo
    Bellan, Mattia
    Bertinieri, Giovanni
    Bertoletti, Massimo
    Casciaro, Giuseppe Francesco
    Castello, Luigi Mario
    Colageo, Umberto
    Colangelo, Donato
    Comolli, Davide
    Costanzo, Martina
    Croce, Alessandro
    D'Onghia, Davide
    Della Corte, Francesco
    De Mitri, Luigi
    Dodaro, Valentina
    Givone, Filippo
    Gravina, Alessia
    Grillenzoni, Luca
    Gusmaroli, Graziano
    Landi, Raffaella
    Lingua, Anna
    Manzoni, Roberto
    Marinoni, Vito
    Masturzo, Bianca
    Minisini, Rosalba
    Morello, Marina
    Nelva, Anna
    Ortone, Elena
    Paolella, Rita
    Patti, Giuseppe
    Pedrinelli, Anita
    Pirisi, Mario
    Ravizzi, Lidia
    Rizzi, Eleonora
    Sola, Daniele
    Sola, Mariolina
    Tonello, Nadir
    Tonello, Stelvio
    Topazzo, Gigliola
    Tua, Aldo
    Valenti, Piera
    Vaschetto, Rosanna
    Vassia, Veronica
    Zecca, Erika
    NUTRIENTS, 2023, 15 (05)
  • [7] Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial
    Ghafoori, Majid
    Saadati, Hassan
    Taghavi, Mohammadreza
    Azimian, Amir
    Alesheikh, Peiman
    Mohajerzadeh, Mina Sadat
    Behnamfar, Morteza
    Pakzad, Marzieh
    Rameshrad, Maryam
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (07) : 3160 - 3168
  • [8] Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
    Kaizer, Alexander M.
    Shapiro, Nathan I.
    Wild, Jessica
    Brown, Samuel M.
    Cwik, B. Jessica
    Hart, Kimberly W.
    Jones, Alan E.
    Pulia, Michael S.
    Self, Wesley H.
    Smith, Clay
    Smith, Stephanie A.
    Ng, Patrick C.
    Thompson, B. Taylor
    Rice, Todd W.
    Lindsell, Christopher J.
    Ginde, Adit A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 128 : 223 - 229
  • [9] A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19
    Kharazmi, Amir Behnam
    Moradi, Omid
    Haghighi, Mehrdad
    Kouchek, Mehran
    Manafi-Rasi, Alireza
    Raoufi, Masoomeh
    Shoaei, Simin Dokht
    Hadavand, Fahimeh
    Nabavi, Mahmood
    Miri, Mir Mohammad
    Salarian, Sara
    Shojaei, Seyedpouzhia
    Khalili, Shayesteh
    Sistanizad, Mohammad
    Sadeghi, Setayesh
    Karagah, Amirhossein
    Asgari, Saemeh
    Jaffaraghaei, Morteza
    Araghi, Shahram
    IMMUNITY INFLAMMATION AND DISEASE, 2022, 10 (02) : 201 - 208
  • [10] Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy A Multicenter, Randomized Clinical Trial
    Johansson, Par, I
    Soe-Jensen, Peter
    Bestle, Morten H.
    Clausen, Niels E.
    Kristiansen, Klaus T.
    Lange, Theis
    Stensballe, Jakob
    Perner, Anders
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (03) : 324 - 329